Abstract
Interleukin-6 (IL-6) expression and secretion, induced by inflammatory processes, stimulate the acute phase response cascade. The overexpression of IL-6 contributes to a variety of inflammatory diseases, e.g. rheumatoid arthritis, Castleman’s disease, multiple myeloma, and prostate cancer. Screening for high amounts of IL-6 in the patients’ blood serum can be crucial for an adequate treatment. In this study, five novel murine monoclonal antibodies (mAbs) reactive to human IL-6 were generated. The mAbs were characterized for potential diagnostic purposes and recombinant antibodies were derived thereof. Initial epitope mapping using a combination of blocking experiments and Hyper-IL-6, a fusion protein consisting of IL-6 and the soluble IL-6 receptor revealed distinct but overlapping binding sites. At least one of the mAbs was found to interact with the region of IL-6/ IL-R complex formation. Three mAbs were applied successfully in intracellular staining by flow cytometry, whereas one of the mAbs showed comparable binding as a reference reagent. Furthermore, the mAbs were tested for applications in various immunological assays such as ELISA, Western blot and surface plasmon resonance spectroscopy (SPR), using IL-6 from commercial sources as well as in-house produced protein (IL-6_IME). The limit of detection was determined by sandwich ELISA (0.5 ng/mL, SD ±0.005). Our results also demonstrated that the recombinant IL- 6 produced was functional and correctly folded. These findings support the use of the generated mAb clones as promising candidates for application in various immunological assays for diagnostic and scientific purposes.
Similar content being viewed by others
References
Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324(6092): 73.
Zilberstein A, Ruggieri R, Korn JH, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986; 5(10): 2529.
Gross V, Andus T, Castell J, Vom Berg D, Heinrich PC, Gerok W. O-and N-glycosylation lead to different molecular mass forms of human monocyte interleukin-6. FEBS Lett 1989; 247(2): 323.
May LT, Shaw JE, Khanna AK, Zabriskie JB, Sehgal PB. Marked cell-type-specific differences in glycosylation of human interleukin-6. Cytokine 1991; 3(3): 204.
Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. Protein Sci 1997; 6(5): 929.
Garbers C, Hermanns HM, Schaper F, et al. Plasticity and crosstalk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012; 23(3): 85.
Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediat Inflamm 2013; 2013: 434010.
Rose-John S. The soluble interleukin-6 receptor and related proteins. Best Pract Res Clin Endocrinol Metab 2015; 29(5): 787.
Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171(6): 3202.
Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 2015; 26(5): 475.
Kishimoto T. The biology of interleukin-6. Blood 1989; 74(1): 1.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6(10): a016295.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16(5): 448.
Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med 2009; 3(4): 363.
Tavakol M, Ashraf S, Brener SJ. Risks and complications of coronary angiography: a comprehensive review. Glob J Health Sci 2012; 4(1): 65.
Puettmann C, Kolberg K, Hagen S, et al. A monoclonal antibody for the detection of SNAP/CLIP-tagged proteins. Immunol Lett 2013; 150(1-2): 69.
Kapelski S, Boes A, Spiegel H, et al. Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody. Malar J 2015; 14: 50.
Schaefer JV, Honegger A, Plückthun A. Construction of scFv fragments from hybridoma or spleen cells by PCR assembly. In:Kontermann S, Dübel S, eds. Antibody engineering. Heidelberg: Springer Verlag, 2010, 1:21.
Tiller T, Busse CE ,Wardemann H. Cloning and expression of murine Ig genes from singleBcells. J Immunol Methods 2009; 350(1-2): 183.
Maskus DJ, Krolik M, Bethke S, et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum apical membrane antigen 1. Sci Rep 2016; 6: 39462.
Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30(2): E9.
Klose D, Woitok M, Niesen J, et al. Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins. PLoS One 2017; 12(7): e0180305.
Fischer M, Goldschmitt J, Peschel C, et al. A bioactive designer cytokine for human hematopoetic progenitor cell expression. Nat Bioltechnol 1997; 15: 142.
Margraf-Schonfeld S, Bohm C, Watzl C. Glycosylation affects ligand binding and function of the activating natural killer cell receptor 2B4 (CD244) protein. J Biol Chem 2011; 286(27): 24142.
Mesquida M, Leszczynska A, Llorenc V, Adan A. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol 2014; 176(3): 301.
Wimmer MD, Ploeger MM, Friedrich MJ, et al. The QuickLine IL-6 lateral flow immunoassay improves the rapid intraoperative diagnosis of suspected periprosthetic joint infections. Technol Health Care 2016; 24(6): 927.
Chaemsaithong P, Romero R, Korzeniewski SJ, et al. A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection. J Matern Fetal Neonatal Med 2016; 29(3): 360.
Feng M, Sun T, Zhao Y, Zhang H. Detection of serum interleukin-6/10/18 levels in sepsis and its clinical significance. J Clin Lab Anal 2016; 30(6): 1037.
Liautard J, Gaillard JP, Mani JC, et al. Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies. Eur Cytokine Netw 1994; 5(3): 293.
Karlsson R, Pol E, Frostell A. Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data. Anal Biochem 2016; 502: 53.
van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 2018; 32(1): 89.
Sommer J, Engelowski E, Baran P, Garbers C, Floss DM, Scheller J. Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int J Mol Med 2014; 34(3): 651.
Kalai M, Montero-Julian FA, Brakenhoff JP, et al. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies. Eur J Biochem 1997; 249(3): 690.
Miteva K, Pappritz K, El-Shafeey M, et al. Mesenchymal stromal cells modulate monocytes trafficking in coxsackievirus B3-induced myocarditis. Stem Cells Transl Med 2017; 6(4): 1249.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Chouman, K., Korioth-Schmitz, B., Sack, M. et al. Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites. Eur Cytokine Netw 29, 59–72 (2018). https://doi.org/10.1684/ecn.2018.0409
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ecn.2018.0409